Latest Overall Supply Report(20211101-20211104)

2021-11-01

— November 1st —

1) For Calcium Pantothenate, since Anhui Tiger raised its quotation to RMB 120, the market transaction price rose, some factories continued to stop reporting, and the early orders have been mainly executed; Up to now, the domestic mainstream transaction has exceeded RMB 110. According to different brands, the domestic transaction price is RMB 105-115, the export price is about USD 14-16, the factory delivery is tight, and the order is scheduled to the end of December; The subsequent price is expected to rise further. According to the current trend, the domestic price may reach RMB 120-130 and the export price may be about USD 15-18 in the next 1-2 weeks.

2) For Vitamin D3, the domestic price began to rise slightly, and the transaction was slightly active. Some manufacturers began to stop reporting and wait. At present, the market transaction price has risen to about RMB 100-120, and the overseas market is temporarily stable. The European price is about EUR 16-18, and the domestic export quotation is USD 15-18. However, with the rise of domestic price, the Vitamin D3 price in the global market is expected to rise.

3) With regard to Florfenicol, the price has fluctuated at a high level recently, and some sources of goods are circulating in the market. However, due to the influence of raw materials, factory delivery is still tight. The recent market price is RMB 720-730.

4) Shouguang Fukang Pharmaceutical Co., Ltd. plans to invest RMB 50.3 million  to build the "technical transformation project of Omeprazole with an annual output of 500 tons". The project relies on the existing workshop, central control room and other buildings, 41 sets of existing equipment, 11 sets of obsolete equipment and 15 sets of main production equipment such as nitrogen oxidation kettle, acylation reaction concentration kettle, oxidation kettle and microchannel reactor. After the completion of the project, an annual production capacity of 500 tons of Omeprazole will be formed.

5) Recently, North China Pharmaceutical Group Corporation Veterinary Co., Ltd. successfully obtained the "veterinary drug production license" and the new version of "veterinary drug GMP certificate", becoming the first batch of enterprises in Hebei Province to pass the acceptance of the new version of veterinary drug GMP, including veterinary powder injection. In this audit, relevant leaders of the Ministry of agriculture and rural areas of the people's Republic of China, agricultural and rural Department of Hebei Province, Veterinary Drug Supervision Institute of Hebei Province and Shijiazhuang agricultural and rural Bureau, as well as experts and observers of the inspection and acceptance team of the new version of veterinary drug GMP, conducted the inspection and acceptance of the new version of veterinary drug GMP and on-site observation of the company. A comprehensive inspection was conducted on the implementation of the new version of veterinary drug GMP, such as multi variety common line production risk, cleaning risk and on-line environmental monitoring in the clean area. Finally, it was evaluated and recommended that 10 dosage forms and five production lines of China Pharmaceutical Group animal protection company were qualified production lines of veterinary drug GMP.

6) NHU said that at present, the company's Heilongjiang biological fermentation phase II Vitamin B12 is under construction, with a design capacity of 3000 tons! In addition, there is news in the market that the shipment time of nhu Vitamin B12 is expected to be from the end of the year to the first quarter of next year.

In addition, the 250 thousand tons of methionine project in NHU, affected by COVID-19 and the macro-economy, delayed the progress of infrastructure construction, extended the time of purchase and purchase of equipment and materials, and postponed the overall progress of the fund-raising investment projects in the installation and commissioning work. The project was completed in December 2021 and postponed in June 2023.

7) Chenguang Biotech Group recently announced that the company plans to invest US USD26.0824 million to build a natural pigment project in Zambia, and its Lutein products have been made into a whole industry chain model from breeding, planting, processing and production to terminal health food. In the first half of 2021, the operating revenue of Chenguang biology was RMB 2.099 billion , a year-on-year increase of 14.96%; The net profit was RMB 189 million , a year-on-year increase of 24.11%. The newly invested project in Zambia is expected to produce 64800 to 86400 tons of Wanshou chrysanthemum per year, which can be processed into 749.4 tons of Lutein extract and sold to China.

— November 2st —

1) About Ivermectin, the price of raw materials rose sharply, the factory price rose steadily, and the delivery time was tight. At present, the domestic market price is RMB 1550-1600 and USD 220-230. Later prices are expected to remain strong.

2) As for Taurine, affected by the rise of raw materials and double limit, on November 1, each factory quoted USD 4-4.3, and the delivery time was relatively tight. At present, the transaction price in the export market is USD 4-4.2/KG and RMB 30-33 / KG. It is expected that the high price of Taurine will remain stable in the near future.

3) As for Folic Acid, affected by the rapid rise of upstream chemical raw materials, Nantong Changhai food additives Co., Ltd. raised the quotation of folic acid again on November 1. The RMB price is RMB 462 / KG and the USD FOB price is USD 64 / KG. The price is valid until November 5.

4) 98.5% Lysine, with a quotation of RMB 12200-12500  / MT, the spot price in the market is slightly higher, the manufacturer's price continues to be strong, some enterprises sell in spot, and the user's willingness to sign orders is not strong. At present, the price of 98.5% Lysine in the trade market is basically the same as that of threonine, and the market price in most regions is relatively strong.

5) The price of vitamin E in Europe has risen. At present, the price of vitamin E in Europe is at EUR 10.5-11.5 (EUR 10-10.8 the previous week), rising by more than EUR 0.5, which is basically in line with the export quotation of China (the price of VE in Europe has been lower than the export price of China and the domestic price of China for a long time). At present, the domestic export quotation is USD 12-13, and the transaction is about USD 11.8-12.2, The transaction prices in the domestic market vary from RMB 87-92 according to different brands. For a long time, the prices of vitamin E in Europe have been lower than those in China and China's exports. This time, it can catch up with the domestic market prices, further consolidate the current market prices in China and China's exports, and have a positive impact on the continuous rise of vitamin E prices in the later period.

6) According to the relevant requirements of GMP compliance inspection, Zhejiang drug inspection center conducted on-site inspection on Zhejiang Guobang Pharmaceutical Co., Ltd. from November 1 to November 5, 2021, involving the production line of Rivaroxaban in workshop 306 and 303 of API (Rivaroxaban); The production line of Procarbil Succinate in workshop 303 of API (Procarbil Succinate).

7) Recently, according to the announcement on South Korea's MSDF official website, Shengda Biotin has obtained the landing certificate of South Korea's pharmaceutical raw materials. This is that Shengda Biotin has once again entered the new regulatory market after obtaining the EU API sales access qualification, which has a positive impact on expanding the South Korean pharmaceutical market.

— November 3st —

1) Colistin Sulfate, a raw material, has increased a lot recently, the factory price has increased greatly, and the delivery time is tight. At present, the market price is about RMB  120  and USD 17. It is expected to remain strong in the later stage.

2) Threonine, quoted in European market to EUR 2.70-3.25/KG. The European market price rose rapidly, reaching a new high since February 2015. The export quotation of Threonine rose, and the domestic export price was better. The start-up of the industry has decreased steadily. Some mainstream enterprises have slow early order delivery, high end-user inventory, and are not eager to make up orders in the short term.

3) With regard to Vitamin A, it has been reported recently that BASF's quotation for Vitamin A feed grade recovery is RMB 285 / KG for domestic VA500 and USD 89 / KG for foreign VA1000. Up to now, the local price in Europe is EUR 72-75, the export price in China is USD 75-80, and the transaction price in China's domestic VA500 market is about RMB 280-290. It is expected that the price of VA will increase steadily or slightly in the later stage!

4) On November 2, Hanyu pharmaceutical announced that the company's Terlipressin Acetate API had received the CEP certificate issued by the European drug quality administration. Terlipressin Acetate is the acetate form of Terlipressin. Terlipressin can reduce portal hypertension, reduce blood flow in portal vein area, contract esophageal smooth muscle and continuously compress esophageal varices.

5) With regard to Ethylene Oxide, there has been a rise in varying degrees in China. At present, the latest ex factory price of ethylene oxide in East China, North China and Northeast China is RMB 10000 / ton, that in Central China is RMB 10200 / MT, and that in South China is RMB 9900 /MT. At present, the factory profit is near RMB 1600 /MT. Recently, the market price has fallen secretly, and there is a strong wait-and-see atmosphere. If the cost side support falls, ethylene oxide may also usher in the inflection point of the rising channel, but it should not meet the inflection point of the falling channel for the time being. It is expected that the market price of downstream choline chloride is mainly high and stable. It is necessary to pay close attention to the changes in the upstream ethylene oxide Market and supply sources, as well as the production and delivery of choline plants.

6) According to Innova's market insight statistics, among the new protein drinks released in the Chinese market from 2019 to the first half of 2021, milk drinks are the main force, accounting for more than 50%; Although the proportion of new products of plant protein beverage and compound protein beverage is small, it shows an upward trend, and the growth of plant protein beverage is obvious. Among plant protein drinks, soybean protein drinks are still favored. According to the statistics in the first half of 2021, the number of new products released is close to half of all plant protein drinks. The number of new product releases of coconut milk and oat milk has increased rapidly, becoming the most popular vegetable protein beverage at present.

— November 4st —

1) About Lysine, the price of coal has fallen recently, but the cost of energy auxiliary materials in the early stage is relatively high, coupled with the strong operation of corn prices, the Lysine industry is limited in operation, and prices in the European market are rising, and the domestic market is tight. Manufacturers have a strong willingness to support the price, and the overall quotations tend to rise. 70%Lysine offers RMB 8800-9200 /MT, 98.5%Lysine RMB 12700 /MT, and the current 98.5%Lysine price in the trade market is basically the same as threonine. Market prices in most regions are relatively firm.

2) Enrofloxacin, affected by rising raw materials and power and production restrictions, the factory has raised prices several times, and delivery is tight. The current low-priced inventory in the market is low, and the price is around RMB 260 . The subsequent prices are expected to remain firm.

3) Toltrazuril, affected by the raw materials, the price of the factory has risen more, and the trade channel has less goods. The current market price is around RMB 1,500 , USD 210 , and delivery is tight.

4) India has cancelled China's decision to impose anti-dumping duties on Vitamin C exports.

5) On the morning of November 3, the Central Committee of the Communist Party of China and the State Council solemnly held the 2020 National Science and Technology Awards Conference in Beijing. Qilu Animal Health Products Co., Ltd., a subsidiary of Qilu Pharmaceutical Group The two projects of "Innovation and Application of New Veterinary Drugs for Disease Series" won two second prizes of National Science and Technology Progress at one time.

6) Dingzhou Xinmiao Biotechnology Company invested in a new Vitamin D3 particle project with a total investment of RMB 50 million. It is located in Dingzhou Economic Development Zone, covering an area of 15 acres and a total construction area of 9,500 square meters. A few days ago, the project has officially entered the construction site.

7) On November 2, the waste heat power generation project of Luwei Pharmaceutical Group Co., Ltd. was officially put into operation. The total investment of the project is more than RMB 30 million , and two 12MW waste heat generating units are newly installed, and the excess heat energy in the production process is used for power generation, saving more than RMB 12.6 million in coal consumption cost each year. The project is not only conducive to environmental protection, but also to ensure the completion of the task of heating the surrounding villagers.

8) Wanhua Chemical, the preparation method of Vitamin A Acetate obtained an invention patent, including the following steps: Beta-Ionone and 2-Chloropropionate undergo a condensation reaction under the action of a strong base, and then undergo hydrolysis and decarboxylation to form an intermediateI; intermediate I undergo condensation reaction with five-carbon aldehyde to produce intermediate II; intermediate I undergoes hydrogenation and dehydration reaction under the action of a catalyst to obtain Vitamin A Acetate. The above method avoids the shortcomings of the existing process, and the process route is economical and effective.

— November 5st —

1) Methionine, the European market price. Increased to EUR 2.90-3.20/KG. Methionine manufacturers have signed their orders, and then most of them stopped quoting. With the settlement of the factory transactions, the market slowed down and the heat dropped. The trade market was eager to ship. The market price fell to RMB 21.0-21.8/KG. Affected by the large increase in imports in September, users' bearish expectations increased and prices fell. Aftermarket purchases and sales are weak.

2) Amoxicillin, following the sharp rise in the price due to the impact of raw materials and production restriction in mid October, currently maintains a high operation, factory delivery continues to be tight, and the market quotation is gradually clear, with a quotation of more than RMB 200 .

3) About Vitamin E, according to market news, the market price of Vitamin E will continue to rise. At present, the European price is EUR 11-11.5 . China's export quotation is USD 12-13 , and the transaction is USD 12-12.5 . China's domestic transaction is USD 88-92 . It is expected that in the next week, the domestic transaction will be more than RMB 90 , and the export transaction will reach USD 13 !

4) Recently, Huaxi Biology established a science and Technology Research Institute in Beijing with a registered capital of RMB 3 million. Its business scope includes engineering and technology research and experimental development; Medical research and experimental development, etc. Shareholder information shows that the company is wholly controlled by Huaxi Biotechnology Co., Ltd.

5) Shanghai Pharma announced on the evening of November 4 that Shanghai Pharmaceuticals Xinya, a wholly-owned subsidiary, signed a "cooperation agreement" with Phagelux. The rights of R&D, production, registration, distribution, sales, marketing, promotion and sublicensing in Mainland China, Hong Kong and Macau include ClyO's indications for systemic infections caused by Staphylococcus aureus.

6) Recently, Vegamax won the first prize of Central China Agricultural Science and Technology by the Ministry of Agriculture. This is Vegamax following the “2017 Zhejiang Province Science and Technology Progress First Prize”, the “2018 China Industry-University-Research Cooperation Innovation Award”, and the “2019 National Science and Technology Progress Second Prize”. "After that, another honor won!